The role of apoptosis in pulmonary fibrosis

European Respiratory Review

Volumn 17, Issue 109, 2008, Pages 138-144

  Uhal, B D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Angiotensin; Epithelium; Lung; Myofibroblasts

Indexed keywords

CANDESARTAN; COLLAGEN; LOSARTAN; SCATTER FACTOR;

APOPTOSIS; CELL DEATH; CLINICAL TRIAL; FIBROSING ALVEOLITIS; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS EPITHELIUM; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; REVIEW; SCAR FORMATION;

EID: 57149087715     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00010906     Document Type: Review

References (55)

1. Plataki M, Koutsopoulos AV, Darivianaki K, Delides G, Siafakas NM, Bouros D. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 2005; 127: 266-274.
2. Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, Selman M. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol Lung Cell Mol Physiol 1998; 275: L1192-1199.
3. Li X, Rayford H, Uhal BD. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 2003; 163: 2523-2530.
4. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N. Apoptosis and expression of FAS/FAS ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 1997; 16: 91-101.
5. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol 2001; 54: 132-138.
6. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
7. Desmoulière A. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol Int 1995; 19: 471-476.
8. Darby IA, Bisucci T, Pittet B, Garbin S, Gabbiani G, Desmouliere A. Skin flap-induced regression of granulation tissue correlates with reduced growth factor and increased metalloproteinase expression. J Pathol 2002; 197: 117-127.
9. Moodley YP, Caterina P, Scaffidi AK, et al. Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis. J Pathol 2004; 202: 486-495.
10. Bühling F, Wille A, Röcken C, et al. Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respir Res 2005; 6: 37.
11. Moodley YP, Misso NL, Scaffidi AK, et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 2003; 29: 490-498.
12. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor β1. Am J Respir Cell Mol Biol 1999; 21: 658-665.
13. Ramos C, Montaño M, Becerril C, et al. Acidic fibroblast growth factor decreases α-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2006; 291: L871-L879.
14. Mizuno S, Matsumoto K, Li MY, Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005; 19: 580-582.
15. Hadden HL, Henke CA. Induction of lung fibroblast apoptosis by soluble fibronectin peptides. Am J Respir Crit Care Med 2000; 162: 1553-1560.
16. Nho RS, Xia H, Kahm J, Kleidon J, Diebold D, Henke CA. Role of integrin-linked kinase in regulating phosphorylation of Akt and fibroblast survival in type I collagen matrices through a β1 integrin viability signaling pathway. J Biol Chem 2005; 280: 26630-26639.
17. Tian B, Lessan K, Kahm J, Kleidon J, Henke C. β1 integrin regulates fibroblast viability during collagen matrix contraction through a phosphatidylinositol 3-kinase/Akt/protein kinase B signaling pathway. J Biol Chem 2002; 277: 24667-24675.
18. Bogatkevich GS, Gustilo E, Oates JC, et al. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005; 288: L190-L201.
19. Wynes MW, Frankel SK, Riches DW. IL-4-induced macrophage-derived IGF-I protects myofibroblasts from apoptosis following growth factor withdrawal. J Leukoc Biol 2004; 76: 1019-1027.
20. Chung MJ, Liu T, Ullenbruch M, Phan SH. Antiapoptotic effect of found in inflammatory zone (FIZZ)1 on mouse lung fibroblasts. J Pathol 2007; 212: 180-187.
21. Adamson YR, Bowden DH. The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposition to oxygen. Lab Invest 1974; 30: 35-42.
22. Wang R, Ibarra-Sunga O, Pick R, Uhal BD. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000; 279: L143-L151.
23. Budinger GR, Mutlu GM, Eisenbart J, et al. Proapoptotic Bid is required for pulmonary fibrosis. Proc Natl Acad Sci USA 2006; 103: 4604-4609.
24. Bargout R, Jankov A, Dincer E, et al. Amiodarone induces apoptosis of human and rat alveolar epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1039-L1044.
25. Uhal BD, Wang R, Laukka J, Zhuang J, Soledad-Conrad V, Filippatos G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Toxicol 2003; 92: 81-87.
26. Okada M, Sugita K, Inukai T, et al. Hepatocyte growth factor protects small airway epithelial cells from apoptosis induced by tumor necrosis factor-α or oxidative stress. Pediatr Res 2004; 56: 336-344.
27. Wang, R, Zagariya A, Ibarra-Sunga O, Ang E, Uhal BD. Fas-induced apoptosis of alveolar epithelial cells requires ANG II generation and receptor interaction. Am J Physiol Lung Cell Mol Physiol 1999; 277: L1245-L1250.
28. Inoshima I, Kuwano K, Hamada N, et al. Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2004; 286: L727-L733.
29. Wang R, Alam G, Zagariya A, et al. Apoptosis of lung epithelial cells in response to TNF-a requires angiotensin II generation de novo. J Cell Physiol 2000; 185: 253-259.
30. Lee CG, Kang HR, Homer RJ, Chupp G, Elias JA. Transgenic modeling of transforming growth factor-β1: role of apoptosis in fibrosis and alveolar remodeling. Proc Am Thorac Soc 2006; 3: 418-423.
31. Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol 2003; 284: L501-L507.
32. Li X, Molina-Molina M, Abdul-Hafez A, et al. Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2006; 291: L887-L895.
33. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000; 161: 1999-2004.
34. Marshall RP, Gohlke P, Chambers RC, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286: L156-L164.
35. Uhal BD, Kim JK, Li X, Molina-Molina M. Angiotensin-TGF-β1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des 2007; 13: 1247-1256.
36. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004; 59: 31-38.
37. Yao HW, Zhu JP, Zhao MH, Lu Y. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration 2006; 73: 236-242.
38. Li X, Zhuang J, Rayford H, Zhang H, Shu R, Uhal BD. Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA. Curr Pharm Des 2007; 13: 1257-1268.
39. Molina-Molina M, Xaubet A, Li X, et al. Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis in disease progression. Eur Respir J 2008; [Epub ahead of print PMID: 18508830].
40. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-833.
41. Kim WH, Matsumoto K, Bessho K, Nakamura T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 2005; 166: 1017-1028.
42. Wojta J, Nakamura T, Fabry A, et al. Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells. Blood 1994; 84: 151-157.
43. Yamanouchi H, Fujita J, Yoshinouchi T, et al. Measurement of hepatocyte growth factor in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis. Respir Med 1998; 92: 273-278.
44. Sakai T, Satoh K, Matsushima K, et al. Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract: detection by RIA and in situ hybridization. Am J Respir Cell Mol Biol 1997; 16: 388-397.
45. Yaekashiwa M, Nakayama S, Ohnuma K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med 1997; 156: 1937-1944.
46. Dohi M, Hasegawa T, Yamamoto K, Marshall B. Hepatocyte growth factor attenuates collagen accumulation in murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000; 162: 2302-2307.
47. Umeda Y, Marui T, Matsuno Y, et al. Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice. Lab Invest 2004; 84: 836-844.
48. Gazdhar A, Fachinger P, van Leer C, et al. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 292: L529-L536.
49. Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Des 2003; 9: 715-722.
50. Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004; 126: 438-446.
51. Molteni A, Moulder JE, Cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000; 76: 523-532.
52. Molteni A, Moulder JE, Cohen EP, et al. Prevention of radiation-induced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blocker. Exp Biol Med 2001; 226: 1016-1023.
53. Molteni A, Wolfe LF, Ward WF, et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-β (TGF-β) and α-actomyosin (α-SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr Pharm Des 2007; 13: 1307-1316.
54. Uhal BD, Gidea C, Bargout R, et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol Lung Cell Mol Physiol 1998; 275: L1013-1017.
55. Woo DS, Seol WJ, Kyung SY, et al. The therapeutic effect of angiotensin II receptor antagonist in idiopathic pulmonary fibrosis. Tuberc Respir Dis 2003; 55: 478-487.